The "ecstasy" hangover: Hyponatremia due to 3,4-methylenedioxymethamphetamine

Journal of Urban Health

Volumn 79, Issue 4, 2002, Pages 549-555

  Traub, Stephen J ^a   Hoffman, Robert S ^a   Nelson, Lewis S ^a  

^a NEW YORK CITY POISON CONTROL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; BRAIN EDEMA; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HORMONE RELEASE; HUMAN; HYPERTHERMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER TOXICITY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RHABDOMYOLYSIS; WATER INTOXICATION;

ADULT; EMERGENCY MEDICAL SERVICES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HALLUCINOGENS; HUMANS; HYPONATREMIA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEW YORK CITY;

EID: 0036945885     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/79.4.549     Document Type: Article

References (37)

1. Curran HV, Travill RA. Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): Week-end "high" followed by mid-week low. Addiction. 1997;92:821-831.
2. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology. 1993;8:171-176.
3. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxy-methamphetamine ("ecstasy"). Lancet. 1992;340(8816):384-387.
4. Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet. 1992;339(8794):677-678.
5. Halachanova V, Sansone RA, McDonald S. Delayed rhabdomyolysis after ecstasy use. Mayo Clin Proc. 2001;76:112-113.
6. Satchell SC, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med. 1994;51:495.
7. Lehmann ED, Thom CH, Croft DN. Delayed severe rhabdomyolysis after taking "ecstasy." Postgrad Med J. 1995;71(833):186-187.
8. Andreu V, Mas A, Bruguera M, et al. Ecstasy: A common cause of severe acute hepatotoxicity. J Hepatol. 1998;29:394-397.
9. Jonas MM, Graeme-Cook FM. A 17-year-old girl with marked jaundice and weight loss. N Engl J Med. 2001;344:591-599.
10. Parr MJ, Low HM, Botterill P. Hyponatraemia and death after "ecstasy" ingestion. Med J Aust. 1997;166(3):136-137.
11. O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B. Death from hyponatraemia-induced cerebral oedema associated with MDMA ("ecstasy") use. N Z Med J. 1999;112(1091):255-256.
12. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine 7 years previously: Factors influencing abnormal recovery. J Neurosci. 1999;19:5096-5107.
13. MacInnes N, Handley SL, Harding GJ. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol. 2001;15(3):181-186.
14. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 2000;68:719-725.
15. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: A controlled study. Psychopharmacology (Berl). 1999;143:417-425.
16. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352(9138):1433-1437.
17. Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med. 1998;5:839-840.
18. Gomez-Balaguer M, Pena H, Morillas C, Hernandez A. Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (ecstasy). J Pediatr Endocrinol Metab. 2000;13:437-438.
19. Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet. 1996;347(9007)-1052.
20. Kessel B. Hyponatraemia after ingestion of ecstasy. BMJ. 1994;308(6925):414.
21. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking "ecstasy." BMJ. 1993;307(6916):1399.
22. Holmes SB, Banerjee AK, Alexander WD. Hyponatraemia and seizures after ecstasy use. Postgrad Med J. 1999;75(879):32-33.
23. Magee C, Staunton H, Tormey W, Walshe JJ. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. Ir Med J. 1998;91(5):178.
24. Nuvials X, Masclans JR, Peracaula R, de Latorre FJ. Hyponatraemic coma after ecstasy ingestion. Intensive Care Med. 1997;23:480.
25. Sharma R, Nelson LS. Methylenedioxymethylamphetamine (MDMA) induced hyponatremia. Int J Med Toxicol. 2000;3(5):29.
26. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136-45.
27. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Fauci AS, Braunwald E, Isselbacher KJ, et al. eds. Harrison's Principles of Internal Medicine, 14th Ed. New York: McGraw Hill; 1998:265-277.
28. Andreoli TE. Water: Normal balance, hyponatremia, and hypernatremia. Renal Failure. 2000;22:711-735.
29. Brownfield MS, Greathouse J, Lorens SA, Armstrong J, Urban JH, Van de Kar LD. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology. 1988;47(4):277-283.
30. Belton K, Thomas SH. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad Med J. 1999;75(886):509-510.
31. Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: Review and proposed mechanisms in the elderly. J Psychopharmacol. 1998;12(4):396-400.
32. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet. 1998;351(9118):1784.
33. Zenenberg R, Goldfarb D. Evaluation of hyponatremia associated with use of methylenedioxy-methylamphetamine (MDMA). Int J Med Toxicol. 2000;3(5):30.
34. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581-158.9
35. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001;51:391-402.
36. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res. 2001;51:403-408.
37. Arieff AI. Treatment of hyponatremic encephalopathy with antagonists to antidiuretic hormone. J Lab Clin Med. 2001;138:8-10.